Getting up-to-date in the management of soft tissue sarcoma

Future Oncology
Jean-Yves Blay

Abstract

Surgery (+ radiation therapy in selected cases) is standard treatment for adult-type localized soft tissue sarcoma (STS). Accumulating randomized clinical evidence also supports adjuvant chemotherapy as a treatment option, although this remains contentious. Doxorubicin (± ifosfamide) is the standard first-line systemic treatment for advanced STS; however, newer chemotherapeutic agents may improve outcomes achieved with single-agent doxorubicin. In a Phase II study, adding olaratumab to doxorubicin markedly improved overall survival. Agents for second- and further lines include trabectedin, which combines long-term tumor stabilization with good quality of life, and gemcitabine + docetaxel which can produce a marked clinical response although at the cost of high toxicity. Pazopanib, eribulin, aldoxorubicin and regorafenib are other options for use in advanced STS.

References

Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S FrustaciP Picci
Oct 31, 2003·Oncology·S FrustaciF Gherlinzoni
Mar 10, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Karl Broich, UNKNOWN Committee for Medicinal Products for Human Use
Oct 27, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stefan SleijferJean-Yves Blay
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier García-Del-MuroUNKNOWN Spanish Group for Research on Sarcomas
Jun 7, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GronchiJ Y Blay
Feb 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alessandro GronchiPiero Picci
Sep 8, 2012·The Lancet Oncology·Penella J WollUNKNOWN EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee
Oct 18, 2012·Drugs·Emma D Deeks
May 10, 2013·Expert Review of Anticancer Therapy·Peter Reichardt
Jul 28, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·S StacchiottiP G Casali
Mar 13, 2014·The Lancet Oncology·Ian JudsonUNKNOWN European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Sep 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·UNKNOWN ESMO/European Sarcoma Network Working Group
Mar 3, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Axel Le CesneUNKNOWN French Sarcoma Group
Jun 5, 2015·Future Oncology·Giovanni GrignaniPeter Reichardt
Sep 16, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George D DemetriShreyaskumar R Patel
Nov 29, 2016·Clinical Sarcoma Research·Adam DangoorIan Judson
Mar 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GronchiJ Y Blay

❮ Previous
Next ❯

Citations

Sep 11, 2019·Future Oncology·Javier Martin-BrotoDavid S Moura
Nov 22, 2019·Veterinary and Comparative Oncology·Antonella BorgattiJessica Lawrence
Aug 19, 2020·Annales de chirurgie plastique et esthétique·P FrobertE Delay
Jun 11, 2021·Future Oncology·Jean-Yves Blay
Jan 1, 2022·The Bone & Joint Journal·Laura J HartleyScott Evans

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02451943

Software Mentioned

CONTICANET

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.